{'fraction_non_alphanumeric': 0.019748653500897665, 'fraction_numerical': 0.01436265709156194, 'mean_word_length': 4.58, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A phase II study of prazosin hydrochloride in hypertensive subjects.

The antihypertensive action of Prazosin was studied in 20 hypertensive patients. Sixteen patients completed the 36-week treatment period. The drug produced a gradual and sustained fall in both systolic and diastolic blood pressure. The dosage used was 1 mg TDS. Only 2 patients required 2 mg TDS of Prazosin combined with 1 mg per day of polythiazide, and one of these did not respond. No postural hypotension or weight gain was observed. Side-effects were mild and were not troublesome.